Analysts expect BioRestorative Therapies, Inc. to report revenue of 298,632.81 for Q1 26, against a range of 286,101.28 to 311,164.34. The most recent reported quarter, Q4 25, came in at 20,000.00, a 86.1% miss against the 143,523.75 consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 89,000.00 | 234,000.00 | 43,000.00 | 25,000.00 | 303,000.00 | 11,800.00 | 20,000.00 | - | - | - | - | - |
| High Estimate | 11,190.31 | 372,865.47 | 531,126.33 | 427,814.16 | 337,805.16 | 483,624.43 | 148,254.44 | 311,164.34 | 606,134.36 | 741,916.45 | 758,935.92 | 780,209.34 |
| Low Estimate | 9,669.29 | 319,987.61 | 470,633.09 | 352,044.64 | 313,849.04 | 403,352.17 | 138,793.06 | 286,101.28 | 517,719.64 | 623,382.55 | 674,521.08 | 686,823.88 |
| Consensus Estimate | 10,429.80 | 346,426.54 | 500,879.71 | 389,929.40 | 325,827.10 | 443,488.30 | 143,523.75 | 298,632.81 | 561,927.00 | 682,649.50 | 716,728.50 | 733,516.61 |
Analysts expect BioRestorative Therapies, Inc. to report earnings per share of -0.19 for Q1 26, against a range of -0.20 to -0.18. The most recent reported quarter, Q4 25, came in at -0.33, a 5.7% beat against the -0.35 consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.50 | -0.13 | -0.20 | -0.64 | -0.30 | -0.33 | -0.33 | - | - | - | - |
| High Estimate | -0.49 | -0.43 | -0.32 | -0.29 | -0.36 | -0.35 | -0.32 | -0.18 | -0.09 | -0.07 | -0.07 |
| Low Estimate | -0.57 | -0.47 | -0.34 | -0.35 | -0.40 | -0.41 | -0.38 | -0.20 | -0.11 | -0.07 | -0.07 |
| Consensus Estimate | -0.53 | -0.45 | -0.33 | -0.32 | -0.38 | -0.38 | -0.35 | -0.19 | -0.10 | -0.07 | -0.07 |